(2-Aminopyrimidin-5-yl)boronic acid → 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine
反応式
Cl[C:2]1[N:10]=[C:9]2[C:5]([N:6]=[CH:7][N:8]2[CH3:11])=[C:4]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[N:3]=1.[NH2:18][C:19]1[N:24]=[CH:23][C:22](B(O)O)=[CH:21][N:20]=1>>[CH3:11][N:8]1[CH:7]=[N:6][C:5]2[C:9]1=[N:10][C:2]([C:22]1[CH:21]=[N:20][C:19]([NH2:18])=[N:24][CH:23]=1)=[N:3][C:4]=2[N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1参加物
3
実験手順
4-(2-Chloro-9-methyl-9H-purin-6-yl)morpholine (95 mg) was reacted with 2-aminopyrimidine-5-boronic acid, pinacol ester via General Procedure A and purified via reverse phase HPLC to give 26.1 mg of 127 as a white solid. MS (Q1) 313.2 (M)+
後処理
- custompurified via reverse phase HPLC
出典と根拠
- ORDレコード
- ord-8d64afac779848e59de18bda8575ca62
- 出典データセット
- uspto-grants-2013_05
- 特許番号
- US08445487B2
反応ノート
読み込み中…